Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0627
Source ID: NCT00542815
Associated Drug: Mci-196
Title: A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT00542815/results
Conditions: Chronic Kidney Disease|Dialysis|Hyperphosphatemia
Interventions: DRUG: MCI-196|DRUG: Another Phosphate binder (Sevelamer)
Outcome Measures: Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer, Change from Baseline to Week 52 (LOCF), 52 weeks (Baseline-52 weeks) | Secondary: The Percent Change in Serum LDL-cholesterol for MCI-196 and Sevelamer, Percent Change from Baseline to Week 52 (LOCF), 52 weeks (Baseline-52 weeks)
Sponsor/Collaborators: Sponsor: Mitsubishi Tanabe Pharma Corporation
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 632
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2007-11
Completion Date: 2010-08
Results First Posted: 2014-09-23
Last Update Posted: 2014-10-02
Locations: Graz, Austria|Frydek-Mistek, Czech Republic|Hradec Kralove, Czech Republic|Ostrava, Czech Republic|Praha, Czech Republic|Tabor, Czech Republic|Usti nad Labem, Czech Republic|Bordeaux, France|Montpelier, France|Paris, France|Aschaffenburg, Germany|Coesfeld, Germany|Darmstadt, Germany|Dortmund, Germany|Dusseldorf, Germany|Hamburg, Germany|Homberg-Efze, Germany|Langen, Germany|Mannheim-Kafertal, Germany|Ajka, Hungary|Baja, Hungary|Budapest, Hungary|Esztergom, Hungary|Gyor, Hungary|Hatvan, Hungary|Kisvarda, Hungary|Veszprem, Hungary|Ancona, Italy|Cernusco sul Naviglio, Italy|Como, Italy|Cremona, Italy|Lecco, Italy|Livorno, Italy|Milan, Italy|Modena, Italy|Ostia Roma, Italy|Pavia, Italy|Perugia, Italy|Rome, Italy|Skopje, Macedonia, The Former Yugoslav Republic of|Alor Setar, Malaysia|Klang, Malaysia|Kota Kinabalu, Malaysia|Kuala Terengganu, Malaysia|Kuching, Malaysia|Melaka, Malaysia|Selangor Darul Ehsan, Malaysia|Seremban, Malaysia|Taiping, Malaysia|Ciechanow, Poland|Czestochowa, Poland|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Oswiecim, Poland|Pabianice, Poland|Poznan, Poland|Rybnik, Poland|Sokolow Podlaski, Poland|Starogard Gdanski, Poland|Warszawa, Poland|Wejherowo, Poland|Wroclaw, Poland|Zgierz, Poland|Zielona Gora, Poland|Arkhangelsk, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Kaluga, Russian Federation|Karbysheva str.Volzskiy, Russian Federation|Kemerovo, Russian Federation|Khabarovsk, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Mytishchi, Russian Federation|Nizhniy Novgorod, Russian Federation|Novokuznetsk, Russian Federation|Novorossiysk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Petrozavodsk, Russian Federation|Rostov-on-Don, Russian Federation|Rozhkova, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Vladivostok, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Sad, Serbia|Cape Town, South Africa|Durban, South Africa|Gauteng, South Africa|Johannesburg, South Africa|Port Elizabeth, South Africa|Barcelona, Spain|Oviedo, Spain|Sevilla, Spain|Chernivtsy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Mykolayiv, Ukraine|Ternopil, Ukraine|Uzhorod, Ukraine|Zaporizhya, Ukraine|Zhytomyr, Ukraine|Glasgow, United Kingdom|Stevenage, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00542815

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress